Literature DB >> 23857675

Preliminary study of patterns of medication use for depression treatment in China.

Ying Zhang1, Thomas Becker, Markus Kösters.   

Abstract

This systematic review investigated drug utilization for depression and assessed trends in prescriptions in China. Major Western and Chinese electronic databases were searched without language restriction for studies reporting defined daily doses. A total of 76 studies published between 2000 and 2010 reporting data on prescriptions for depression in China between 1996 and 2008 were included. All studies were published in Chinese. Most trials were conducted in urban areas in south and east China. Twenty-nine drugs were reported as antidepressants. On the basis of defined daily doses, melitracen/flupentixol combination, fluoxetine, and paroxetine were the most frequently prescribed compounds. According to published evidence, selective serotonin reuptake inhibitors have become the most commonly prescribed class of antidepressant drugs in China.
Copyright © 2012 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  China; antidepressant drug; prescription; review; trend

Mesh:

Substances:

Year:  2012        PMID: 23857675     DOI: 10.1111/appy.12022

Source DB:  PubMed          Journal:  Asia Pac Psychiatry        ISSN: 1758-5864            Impact factor:   2.538


  5 in total

Review 1.  Vortioxetine for depression in adults.

Authors:  Markus Koesters; Giovanni Ostuzzi; Giuseppe Guaiana; Johanna Breilmann; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2017-07-05

Review 2.  A systematic review of Chinese randomized clinical trials of SSRI treatment of depression.

Authors:  Ying Zhang; Thomas Becker; Yongchun Ma; Markus Koesters
Journal:  BMC Psychiatry       Date:  2014-08-27       Impact factor: 3.630

3.  Sertraline plus deanxit to treat patients with depression and anxiety in chronic somatic diseases: a randomized controlled trial.

Authors:  Limin Wang; Zhuoyuan Zhong; Jingyang Hu; Xiaoming Rong; Jun Liu; Songhua Xiao; Zhonglin Liu
Journal:  BMC Psychiatry       Date:  2015-04-14       Impact factor: 3.630

4.  Bioequivalence Study Of A Fixed-Dose Combination Tablet Containing Melitracen 10 mg And Flupentixol 0.5 mg In Healthy Chinese Volunteers Under Fasted And Fed Conditions.

Authors:  Lihua Wu; Chang Xu; Guolan Wu; Huili Zhou; Duo Lv; You Zhai; Yujie Huang; Wenling Tang; Fangqiong Li; Jianzhong Shentu
Journal:  Drug Des Devel Ther       Date:  2019-09-19       Impact factor: 4.162

Review 5.  Current Clinical Psychopharmacology in Borderline Personality Disorder.

Authors:  Antonio Del Casale; Luca Bonanni; Paride Bargagna; Francesco Novelli; Federica Fiaschè; Marco Paolini; Francesca Forcina; Gaia Anibaldi; Francesca Natalia Cortese; Alessia Iannuccelli; Barbara Adriani; Roberto Brugnoli; Paolo Girardi; Joel Paris; Maurizio Pompili
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.